Live Breaking News & Updates on Breast cancer clinical research

Stay informed with the latest breaking news from Breast cancer clinical research on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Breast cancer clinical research and stay connected to the pulse of your community

Dr Hafez on the Influence of Biomarker Expression on Adjuvant T-DM1 Use in HER2+ Breast Cancer

Maria Hafez, MD, discusses differences in biomarker expression prior to and following neoadjuvant chemotherapy treatment in HER2-positive breast cancer.

Maria-hafez , Breast-cancer-clinical-research , Sidney-kimmel-medical-college , Thomas-jefferson-university , Sidney-kimmel-cancer-center , Prediction-analysis , Absolute-intrinsic-molecular-subtyping , D , Onclive , Early-stage-her2-positive-breast-cancer- ,

Exploratory Analyses of KATHERINE Trial Inform Adjuvant T-DM1 Use in HER2+ Breast Cancer

Maria Hafez, MD, spotlights the KATHERINE trial in HER2-positive breast cancer, expanding on the respective toxicity profiles of T-DM1 and trastuzumab that were identified in an exploratory safety analysis of the trial; updated outcomes with T-DM1 in those with residual invasive disease after neoadjuvant treatment and surgery; and more.

Philadelphia , Pennsylvania , United-states , Maria-hafez , Sidney-kimmel-medical-college , Science-summit , Breast-cancer-clinical-research , Sidney-kimmel-cancer-center , Thomas-jefferson-university , Prediction-analysis , Absolute-intrinsic-molecular , Katherine-trial

Biomarker Data and Patient Preference Inform Perioperative Therapy Selection in Early HER2+ Breast Cancer

Maria Hafez, MD, discusses factors such as HER2 status, lymph node negativity, and risk stratification that influence the selection of adjuvant treatment approaches for patients with early-stage HER2-positive breast cancer and expands on pivotal data that have changed the paradigm.

Philadelphia , Pennsylvania , United-states , Maria-hafez , Sidney-kimmel-medical-college , Science-summit , Breast-cancer-clinical-research , Sidney-kimmel-cancer-center , Thomas-jefferson-university , Biomarker-data , Perioperative-therapy , Her2-breast-cancer

Dr Mayer on the Use of CDK4/6 Inhibitors in HR+/HER2– Breast Cancer

Erica L. Mayer, MD, MPH, discusses findings from research investigating CDK4/6 inhibitors in patients with hormone receptor (HR)–positive, HER2-negative breast cancer.

Erical-mayer , Breast-cancer-clinical-research , Dana-farber-cancer-institute , Harvard-medical-school , D , Ph , Dana-farber-and-brigham-womens-hospital , Cdk4-6-inhibitors , Patients-with-hormone-receptor-positive , Er2-negative-breast-cancer ,

Medicine Grand Rounds | Duke Department of Medicine

Medicine Grand Rounds (MGR) is a weekly seminar series to support the academic environment of the Duke Department of Medicine. Topics and speakers are selected to provide faculty and trainees with up-to-date knowledge about timely issues in internal medicine. MGR occurs every Friday at 8 a.m in Duke North 2002 unless otherwise noted below at a different location.

Boston , Massachusetts , United-states , Texas , Naval-medical-center-san-diego , California , San-diego , American , Johns-hopkins-myositiscenter , David-butterly , Jamesb-wyngaarden , Thomasw-leblanc

When to get first mammogram? Doctor explains latest advice - INDIA New England News

When to get first mammogram? Doctor explains latest advice - INDIA New England News
indianewengland.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indianewengland.com Daily Mail and Mail on Sunday newspapers.

Massachusetts , United-states , Steven-isakoff , Harvard-medical-school , Us-preventive-services-task , Breast-cancer-clinical-research-at-mass , Cancer-center , Services-task , Breast-cancer-clinical-research , Mass-general-cancer-center , Harvard-medical ,

Why start mammograms at 40? Doctor explains new advice.

Guidance shifts amid troubling breast cancer trends in young and Black women.

Massachusetts , United-states , Steven-isakoff , Us-preventive-services-task , Harvard-medical-school , Breast-cancer-clinical-research-at-mass , Cancer-center , Services-task , Breast-cancer-clinical-research , Mass-general-cancer-center , Harvard-medical , Breast-cancer